| 0 (0%) | 09-27 09:27 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 31.73 | 1-year : | 37.06 |
| Resists | First : | 27.17 | Second : | 31.73 |
| Pivot price | 23.25  |
|||
| Supports | First : | 22.88 | Second : | 20.22 |
| MAs | MA(5) : | 25.32 |
MA(20) : | 23.43 |
| MA(100) : | 19.26 |
MA(250) : | 16.06 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 74.6 |
D(3) : | 83.2 |
| RSI | RSI(14): 56.1 |
|||
| 52-week | High : | 27.17 | Low : | 7.75 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ASMB ] has closed below upper band by 30.1%. Bollinger Bands are 60.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 25.65 - 25.81 | 25.81 - 25.92 |
| Low: | 23.99 - 24.18 | 24.18 - 24.33 |
| Close: | 24.41 - 24.7 | 24.7 - 24.92 |
Wed, 24 Sep 2025
JMP Securities Initiates Coverage of Assembly Biosciences (ASMB) with Market Outperform Recommendation - Nasdaq
Wed, 24 Sep 2025
Assembly Biosciences, Inc. (NASDAQ:ASMB) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Wed, 24 Sep 2025
New Analyst Forecast: $ASMB Given $38.0 Price Target - Quiver Quantitative
Wed, 24 Sep 2025
Assembly Biosciences (NASDAQ:ASMB) Now Covered by Analysts at Citizens Jmp - MarketBeat
Mon, 22 Sep 2025
Assembly Biosciences (ASMB) Surges 9.8%: Is This an Indication of Further Gains? - Nasdaq
Mon, 22 Sep 2025
Assembly Biosciences, Inc. (NASDAQ:ASMB) Is Expected To Breakeven In The Near Future - 富途牛牛
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 8 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 38.5 (%) |
| Held by Institutions | 25.4 (%) |
| Shares Short | 911 (K) |
| Shares Short P.Month | 30 (K) |
| EPS | -5.56 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.35 |
| Profit Margin | -117.2 % |
| Operating Margin | -115.3 % |
| Return on Assets (ttm) | -27.8 % |
| Return on Equity (ttm) | -147.7 % |
| Qtrly Rev. Growth | 12.8 % |
| Gross Profit (p.s.) | -3.33 |
| Sales Per Share | 4.33 |
| EBITDA (p.s.) | -5.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -56 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -4.44 |
| PEG Ratio | 0 |
| Price to Book value | 10.45 |
| Price to Sales | 5.69 |
| Price to Cash Flow | -3.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|